Shilpa Medicare’s finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Telangana has received Health Canada GMP approval for the inspection conducted from September 12, 2022 to September 16, 2022. The facility is involved in manufacturing, packaging, labelling and testing of finished dosage forms (sterile injections and oral solids) for the treatment of cancer and adjuvant therapy. This GMP approval will allow the company for the commercial distribution of products in Canada and enable new application submissions to Health Canada. This approval reaffirms the company’s focused efforts to maintain the GMP status up to the standards of global regulatory authorities.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
